Lipid-lowering agents that cause drug-induced hepatotoxicity.
Open accessAbstract
The effort to reduce cardiovascular risk factors, including hyperlipidemia, has led to the increased use of lipid-lowering agents. Hyperlipidemic patients often have underlying fatty liver disease, however, and thus may have elevated and fluctuating liver biochemistries. Therefore, caution should be applied before attributing elevated liver tests to lipid-lowering agents. Data indicate that patients who have chronic liver disease and compensated cirrhosis should not be precluded from receiving statins to treat hyperlipidemia. Several recent studies and expert opinion currently fully endorse statin use in patients who have nonalcoholic fatty liver disease and other chronic liver disease if clinically indicated.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The most serious complication of niacin therapy is hepatotoxicity, which is dose dependent, and therapy should be accompanied by monitoring of liver function tests.
“The most serious complication of niacin therapy is hepatotoxicity (which is dose dependent), and therapy should be accompanied by monitoring of liver function tests (178).”
From Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline (2012) · cites this paper as [178]
The Niacin section (page unavailable) describes dose-related hepatotoxicity, especially with sustained-release niacin, and the Conclusion calls sustained-release niacin a cause of clinically significant liver injury. The passages do not recommend monitoring liver function tests during niacin therapy, so that part of the claim is unsupported. (LLM, conf=0.86)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902 · see citing works
Grundy, S. M., Cleeman, J. I., Bairey Merz, C. N., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.07.001 · Cited by 1,550 · see citing works
Jaeschke, H. (2002) · Toxicological Sciences · doi:10.1093/toxsci/65.2.166 · Cited by 1,308 · see citing works
ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins
Writing Committee Members:, Pasternak, R. C., Smith, S. C., Bairey-Merz, C. N., Grundy, S. M., Cleeman, J. I., & Lenfant, C. (2002) · Circulation · doi:10.1161/01.cir.0000032466.44170.44 · Cited by 1,088 · see citing works
Liver transplantation for acute liver failure from drug induced liver injury in the United States
Russo, M. W., Galanko, J. A., Shrestha, R., Fried, M. W., & Watkins, P. B. (2004) · Liver Transplantation · doi:10.1002/lt.20204 · Cited by 473 · see citing works
Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity
Chalasani, N., Aljadhey, H., Kesterson, J., Murray, M. D., & Hall, S. D. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.02.015 · Cited by 441 · see citing works
Self-citationLandmesser, U., Bahlmann, F. H., Mueller, M. F., Spiekermann, S., Kirchhoff, N., Schulz, S., Manes, C., Fischer, D., de Groot, K., Fliser, D., et al. (2005) · Circulation · doi:10.1161/01.cir.0000164260.82417.3f · Cited by 425 · see citing works
Carcinogenicity of Lipid-Lowering Drugs
Newman, T. B. (1996) · JAMA · doi:10.1001/jama.1996.03530250059028 · Cited by 378 · see citing works
An Assessment of Statin Safety by Hepatologists
Cohen, D. E., Anania, F. A., & Chalasani, N. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.014 · Cited by 354 · see citing works
Self-citationChalasani, N., Deeg, M. A., & Crabb, D. W. (2004) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.30159.x · Cited by 343 · see citing works
Self-citationStrandberg, T. E., Pyörälà, K., Cook, T. J., Wilhelmsen, L., Færgeman, O., Þorgeirsson, G., Pedersen, T. R., & KJEKSHUS, J. K. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16936-5 · Cited by 330 · see citing works
Lewis, J. H., Mortensen, M. E., Zweig, S., Fusco, M. J., Medoff, J. R., & Belder, R. (2007) · Hepatology · doi:10.1002/hep.21848 · Cited by 305 · see citing works
McKenney, J. M. (1994) · JAMA · doi:10.1001/jama.1994.03510330050033 · Cited by 303 · see citing works
Detoxification of Lithocholic Acid, A Toxic Bile Acid: Relevance to Drug Hepatotoxicity
Hofmann, A. F. (2004) · Drug Metabolism Reviews · doi:10.1081/dmr-200033475 · Cited by 268 · see citing works
Chalasani, N. (2005) · Hepatology · doi:10.1002/hep.20671 · Cited by 264 · see citing works
Self-citationEfficacy and safety of an extended-release niacin (Niaspan): a long-term study
Capuzzi, D. M., Guyton, J. R., Morgan, J. M., Goldberg, A. C., Kreisberg, R. A., Brusco, O. A., & Brody, J. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00731-0 · Cited by 254 · see citing works
Safety and Tolerability of Pravastatin in Long-Term Clinical Trials
Pfeffer, M. A., KEECH, A. C., Sacks, F. M., Cobbe, S. M., Tonkin, A. M., Byington, R. P., Davis, B. R., Friedman, C. P., & D, E. B. M. (2002) · Circulation · doi:10.1161/01.cir.0000017634.00171.24 · Cited by 240 · see citing works
Statins and Liver Toxicity: A Meta‐Analysis
de Denus, S., Spinler, S. A., Miller, K., & Peterson, A. M. (2004) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.24.6.584.34738 · Cited by 218 · see citing works
Chitturi, S., & George, J. (2002) · Seminars in Liver Disease · doi:10.1055/s-2002-30102 · Cited by 216 · see citing works
Tolman, K. G. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02355-x · Cited by 213 · see citing works
Preclinical evaluation of lovastatin
MacDonald, J. S., Gerson, R. J., Kornbrust, D. J., Kloss, M. W., Prahalada, S. R., Berry, P. H., Alberts, A. W., & Bokelman, D. L. (1988) · The American Journal of Cardiology · doi:10.1016/0002-9149(88)90003-3 · Cited by 199 · see citing works
Comparative Tolerability of the HMG-CoA Reductase Inhibitors
Farmer, J. A., & Torre‐Amione, G. (2000) · Drug Safety · doi:10.2165/00002018-200023030-00003 · Cited by 181 · see citing works
Statins and hepatic steatosis: Perspectives from the Dallas Heart Study
Browning, J. D. (2006) · Hepatology · doi:10.1002/hep.21248 · Cited by 161 · see citing works
Athyros, V. G., Papageorgiou, A. A., Hatzikonstandinou, H. A., Didangelos, T., Carina, M., Kranitsas, D. F., & Kontopoulos, A. G. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00430-x · Cited by 154 · see citing works
Statin Safety: Lessons from New Drug Applications for Marketed Statins
Jacobson, T. A. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.009 · Cited by 144 · see citing works
Autoimmune Hepatitis Triggered by Statins
Alla, V., Abraham, J. P., Siddiqui, J., Raina, D., Wu, G. Y., Chalasani, N., & Bonkovsky, H. L. (2006) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-200609000-00018 · Cited by 137 · see citing works
Self-citationHepatic toxicity of unmodified and time-release preparations of niacin
Rader, J. I., Calvert, R. J., & Hathcock, J. N. (1992) · The American Journal of Medicine · doi:10.1016/0002-9343(92)90018-7 · Cited by 135 · see citing works
Vuppalanchi, R., Chalasani, N., & Teal, E. (2005) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200502000-00002 · Cited by 133 · see citing works
Self-citationRisk of adverse events with fibrates*
Alsheikh-Ali, A. A. A., Kuvin, J. T., & Karas, R. H. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.06.033 · Cited by 125 · see citing works
Brewer, H. B. (2004) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000121505.88326.d2 · Cited by 124 · see citing works
Fulminant Hepatic Failure after Ingestion of Sustained-Release Nicotinic Acid
Mullin, G. E., Greenson, J. K., & Mitchell, M. C. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-3-253 · Cited by 117 · see citing works
Incidence of Statin Hepatotoxicity in Patients With Hepatitis C
Khorashadi, S., Hasson, N. K., & Cheung, R. C. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.03.014 · Cited by 111 · see citing works
Apoptotic injury in cultured human hepatocytes induced by HMG-CoA reductase inhibitors
Kubota, T., Fujisaki, K., Itoh, Y., Yano, T., Sendo, T., & Oishi, R. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.02.037 · Cited by 100 · see citing works
Defining patient risks from expanded preventive therapies
Tolman, K. G. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(00)00946-2 · Cited by 98 · see citing works
Hepatotoxicity associated with sustained-release niacin
Dalton, T. A., & Berry, R. S. (1992) · The American Journal of Medicine · doi:10.1016/0002-9343(92)90689-9 · Cited by 98 · see citing works
Drug-induced lupus-like syndrome associated with severe autoimmune hepatitis
Graziadei, I., Obermoser, G., Sepp, N. T., Erhart, K. H., & Vogel, W. (2003) · Lupus · doi:10.1191/0961203303lu313cr · Cited by 96 · see citing works
Hepatotoxicity of hypolipidemic drugs
Parra, J. L., & Reddy, K. R. (2003) · Clinics in Liver Disease · doi:10.1016/s1089-3261(03)00024-2 · Cited by 93 · see citing works
Niacin-Induced Hepatitis: A Potential Side Effect With Low-Dose Time-Release Niacin
Etchason, J., Miller, T. D., Squires, R. W., Allison, T. G., Gau, G. T., Marttila, J. K., & Kottke, B. A. (1991) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)61171-9 · Cited by 90 · see citing works
Autoimmune hepatitis revealed by atorvastatin
Pelli, N., Setti, M., Ceppa, P., et al. (2003) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200308000-00014 · Cited by 89 · see citing works
Prolonged-Release Nicotinic Acid
McCormack, P. L., & Keating, G. M. (2005) · Drugs · doi:10.2165/00003495-200565180-00014 · Cited by 88 · see citing works
Overview of niacin formulations: Differences in pharmacokinetics, efficacy, and safety
Pieper, J. A. (2003) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/60.suppl_2.s9 · Cited by 78 · see citing works
Ator vastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin
Nakad, A., Bataille, L., Hamoir, V., Sempoux, C. L., & Horsmans, Y. (1999) · The Lancet · doi:10.1016/s0140-6736(99)00569-3 · Cited by 73 · see citing works
Ricaurte, B. M., Guirguis, A., Taylor, H. C., & Zabriskie, D. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1g462 · Cited by 68 · see citing works
Severe Hepatic Side Effects of Ezetimibe
Stolk, M. F. J., Becx, M. C., Kuypers, K. C., & Seldenrijk, C. A. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.04.014 · Cited by 65 · see citing works
Rechallenge With Crystalline Niacin After Drug-Induced Hepatitis From Sustained-Release Niacin
Henkin, Y. (1990) · JAMA · doi:10.1001/jama.1990.03450020093033 · Cited by 65 · see citing works
Efficacy and Safety of Controlled-Release Niacin in Dyslipoproteinemic Veterans
Gray, D. R., Morgan, T., Chretien, S. D., et al. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-4-199408150-00003 · Cited by 63 · see citing works
Vogt, A., Kassner, U., Hostalek, U., Steinhagen‐Thiessen, E., & on behalf of the NAuTiluS Study Group (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x89766 · Cited by 63 · see citing works
Acute Cholestatic Hepatitis Associated With Pravastatin
Hartleb, M., Rymarczyk, G., & Januszewski, K. (1999) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01091.x · Cited by 62 · see citing works
Safety Issues with Statin Therapy
Talbert, R. L. (2006) · Journal of the American Pharmacists Association · doi:10.1331/154434506778073637 · Cited by 58 · see citing works
Nicotinic Acid-Induced Fulminant Hepatic Failure
Clementz, G. L., & Holmes, A. W. (1987) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-198710000-00022 · Cited by 57 · see citing works
Rosuvastatin-associated hepatitis with autoimmune features
Wolters, L. M. M., & van Buuren, H. R. (2005) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200505000-00019 · Cited by 57 · see citing works
Niacin for dyslipidemia: Considerations in product selection
McKenney, J. M. (2003) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/60.10.995 · Cited by 56 · see citing works
Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis.
Kanathur, N., Mathai, M. G., Byrd, R. P., et al. (2001) · PubMed · Cited by 55 · see citing works
Drug-induced acute autoimmune hepatitis during combination therapy with atorvastatin and ezetimibe
van Heyningen, C. (2005) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1258/0004563054890105 · Cited by 53 · see citing works
Cruz-Fernández, J. M., Bedarida, G., Adgey, J., Allen, C., Johnson‐Levonas, A. O., & Massaad, R. (2005) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2005.00565.x · Cited by 52 · see citing works
Atorvastatin-Induced Cholestatic Hepatitis in a Young Woman With Systemic Lupus Erythematosus
Jiménez-Alonso, J. F. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.15.1811-a · Cited by 52 · see citing works
Horsmans, Y., Desager, J. P., & Harvengt, C. (1990) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1990.tb00840.x · Cited by 50 · see citing works
Fatal liver failure with atorvastatin
Perger, L., Kohler, M., Fattinger, K. E., et al. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00464-1 · Cited by 46 · see citing works
Profiling of hepatic gene expression in rats treated with fibric acid analogs
Cornwell, P. D., Souza, A. T. D., & Ulrich, R. G. (2004) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2003.12.019 · Cited by 46 · see citing works
Acute hepatitis induced by HMG-CoA reductase inhibitor, lovastatin
Grimbert, S., Pessayre, D., Degott, C., & Benhamou, J. (1994) · Digestive Diseases and Sciences · doi:10.1007/bf02088142 · Cited by 41 · see citing works
Acute Hepatic Failure Associated With the Use of Low-Dose Sustained-Release Niacin
Hodis, H. N. (1990) · JAMA · doi:10.1001/jama.1990.03450020033012 · Cited by 39 · see citing works
Mecanismos de hepatotoxicidade
Bertolami, M. C. (2005) · Arquivos Brasileiros de Cardiologia · doi:10.1590/s0066-782x2005002400007 · Cited by 37 · see citing works
Statins for Hyperlipidemia in Patients With Chronic Liver Disease: Are They Safe?
Vuppalanchi, R., & Chalasani, N. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.04.020 · Cited by 36 · see citing works
Self-citationGraf, D., Kohlmann, C., Haselow, K., Gehrmann, T., Bode, J. G., & Häussinger, D. (2006) · Hepatology · doi:10.1002/hep.21368 · Cited by 32 · see citing works
Dix, K. J., Coleman, D. P., & Jeffcoat, A. R. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14897-0 · Cited by 32 · see citing works
Safety and efficacy of atorvastatin in heart transplant recipients
Patel, D. N., Pagani, F. D., Koelling, T. M., Dyke, D. B. S., Baliga, R. R., Cody, R. J., Lake, K. D., & Aaronson, K. D. (2002) · The Journal of Heart and Lung Transplantation · doi:10.1016/s1053-2498(01)00369-2 · Cited by 31 · see citing works
Chen, H., Huang, C.-Y., Wilson, M. W., et al. (1994) · Carcinogenesis · doi:10.1093/carcin/15.12.2847 · Cited by 29 · see citing works
Caldwell, S. H., Hespenheide, E. E., & von Borstel, R. W. (2001) · Digestive Diseases and Sciences · doi:10.1023/a:1005505827545 · Cited by 28 · see citing works
Niacin extended-release/ lovastatin: combination therapy for lipid disorders
Moon, Y. S., & Kashyap, M. L. (2002) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.3.12.1763 · Cited by 28 · see citing works
Safety of Statins When Response is Carefully Monitored: A Study of 336 Heart Recipients
Marzoa‐Rivas, R., Crespo‐Leiro, M. G., Paniagua-Marin, M. J., Llinares-García, D., Muñiz, J., Aldama‐López, G., Piñón-Esteban, P., Campo-Pérez, R., & Castro-Beiras, A. (2005) · Transplantation Proceedings · doi:10.1016/j.transproceed.2005.09.163 · Cited by 28 · see citing works
ASHP Therapeutic Position Statement on the Safe Use of Niacin in the Management of Dyslipidemias
Britton, M. L., Bradberry, J. C., McKenney, J. M., et al. (1997) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/54.24.2815 · Cited by 28 · see citing works
Gershovich, O. E., & Lyman, A. E. (2004) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.24.1.150.34803 · Cited by 27 · see citing works
Fenofibrate-induced acute cholestatic hepatitis.
Ho, C.-Y., Kuo, T.-H., Chen, T., et al. (2004) · PubMed · Cited by 24 · see citing works
Transient Focal Hepatic Defects Related to Sustained-Release Niacin
Lawrence, S. P. (1993) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-199304000-00015 · Cited by 21 · see citing works
COPPOLA, A., Brady, P. G., & Nord, H. J. (1994) · Southern Medical Journal · doi:10.1097/00007611-199401000-00007 · Cited by 21 · see citing works
Colestipol‐Induced Hepatotoxicity
Sirmans, S. M., Beck, J. K., Banh, H. L., et al. (2001) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.21.5.513.34501 · Cited by 20 · see citing works
Hepatitis colestásica aguda tras la reintroducción de atorvastatina
de Castro, M. L., Hermo, J. A., Lomba, A. B., de Luaces, C., Perez, R. A. T., & Clofent, J. (2006) · Gastroenterología y Hepatología · doi:10.1157/13083248 · Cited by 17 · see citing works
Colesevelam hydrochloride in the management of dyslipidemia
Armani, A., & Toth, P. (2006) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.4.3.283 · Cited by 16 · see citing works
The effect of fluvastatin on the pharmacokinetics and pharmacodynamics of ezetimibe
Reyderman, L., Kosoglou, T., Cutler, D. L., Maxwell, S. E., & Statkevich, P. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x46386 · Cited by 15 · see citing works
Statins and cancer: a case of meta-uncertainty
Güallar, E., & Goodman, S. N. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00758-6 · Cited by 14 · see citing works
Niacin-Induced Hepatitis and Thrombocytopenia After 10 Years of Niacin Use
Reimund, E., & Ramos, A. (1994) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-199404000-00037 · Cited by 12 · see citing works
Kristensen, T., & Olcott, E. W. (1999) · Journal of Computer Assisted Tomography · doi:10.1097/00004728-199903000-00026 · Cited by 11 · see citing works
Ezetimibe/Simvastatin (vytorin) for hypercholesterolemia.
Goldman, J. D., & Bohlman, L. G. (2005) · PubMed · Cited by 7 · see citing works
Ultrasonographic findings in niacin-induced hepatitis.
Scheer, M., Perlmutter, S., Ross, W., et al. (1999) · Journal of Ultrasound in Medicine · doi:10.7863/jum.1999.18.4.321 · Cited by 6 · see citing works
Safety and Side Effects of Sustained-Release Niacin
Lavie, C. J. (1994) · JAMA · doi:10.1001/jama.1994.03520070031016 · Cited by 6 · see citing works
[Acute hepatitis caused by gemfibrozil].
Balén, M. B., Gimeno, G., González, I. B., et al. (1998) · PubMed · Cited by 5 · see citing works
[Cholestatic hepatitis caused by gemfibrozil].
Lorenzo, A. D. D., Catalina, V., Sánchez, A. G., et al. (2001) · PubMed · Cited by 5 · see citing works
Flutamide-induced hepatotoxicity with possible potentiation by simvastatin.
Ashar, U., Desai, D., & Bhaduri, A. S. (2003) · PubMed · Cited by 5 · see citing works
Grubisic-Cabo, F., & Vrdoljak, E. (2006) · Medical Oncology · doi:10.1385/mo:23:1:121 · Cited by 3 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- Jacobson TA. Statin safety: lessons from new drug applications for marketed statins. American Journal of Cardiology 2006;97(suppl):44C-51C. [PubMed: 16377282]
Cited by
Sorted by citations
Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline
Berglund, L., Brunzell, J. D., Goldberg, A. C., Goldberg, I. J., Sacks, F., Murad, M. H., & Stalenhoef, A. F. H. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3213 · Cited by 887 · see citing works
“The most serious complication of niacin therapy is hepatotoxicity (which is dose dependent), and therapy should be accompanied by monitoring of liver function tests (178).”
2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia
Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., de Ferranti, S. D., et al. (2026) · JACC · doi:10.1016/j.jacc.2025.11.016 · Cited by 304 · see citing works
Writing Committee Members, Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001423 · Cited by 122 · see citing works
Skilving, I., Eriksson, M., Rane, A., & Ovesjö, M.-L. (2016) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-016-2105-2 · Cited by 28 · see citing works
Vascular targets for the treatment of portal hypertension
Brusilovskaya, K., Königshofer, P., Schwabl, P., & Reiberger, T. (2019) · Seminars in Liver Disease · doi:10.1055/s-0039-1693115 · Cited by 28 · see citing works
- Authors
- Bhardwaj, S. S., & Chalasani, N.
- Affiliations
- Indiana University Indianapolis (US)
- Corresponding author
- Chalasani, Naga
- ORCID
- Chalasani, Naga
- Venue
- Clinics in Liver Disease
- Publisher
- Elsevier BV
- Published
- 2007-08
- Volume
- 11
- Issue
- 3
- Pages
- 597-613
- ISSN
- 1089-3261 (ISSN-L)
- PMC
- PMC2048990
- OpenAlex
- W2089712819
- Cited by
- 173
- References
- 89
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 9 · 2023: 5 · 2022: 13 · 2021: 9 · 2020: 7 · 2019: 12 · 2018: 10 · 2017: 14 · 2016: 7 · 2015: 10 · 2014: 11 · 2013: 9 · 2012: 10
- FWCI
- 0.97
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinics in Liver Disease (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- IUScholarWorks (Indiana University) (submittedVersion)
- Funders
- U.S. Public Health Service (K24 069290)
- National Institute of Diabetes and Digestive and Kidney Diseases (K24DK069290)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Keywords
- lipid-lowering drugs, drug-induced liver injury, statins, hyperlipidemia, non-alcoholic fatty liver disease, chronic liver disease, compensated cirrhosis, liver function tests, cardiovascular risk reduction
- MeSH terms
- Ezetimibe, Hypolipidemic Agents, Azetidines, Humans, Niacin, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Cholesterol Ester Transfer Proteins, Chemical and Drug Induced Liver Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
